{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:52:48Z","timestamp":1763535168408},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T00:00:00Z","timestamp":1346889600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2407-12-390","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T06:14:36Z","timestamp":1346912076000},"source":"Crossref","is-referenced-by-count":31,"title":["Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract"],"prefix":"10.1186","volume":"12","author":[{"given":"August","family":"Zabernigg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes M","family":"Giesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Pall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva-Maria","family":"Gamper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Gattringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M","family":"Wintner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika J","family":"Sztankay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Holzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,6]]},"reference":[{"issue":"6","key":"3324_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sjoden PO, et al: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996, 7 (6): 593-600. 10.1093\/oxfordjournals.annonc.a010676.","journal-title":"Ann Oncol"},{"issue":"6","key":"3324_CR2","doi-asserted-by":"crossref","first-page":"2403\u201313.T","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris","year":"1997","unstructured":"Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997, 15 (6): 2403\u201313.T-","journal-title":"J Clin Oncol"},{"issue":"22","key":"3324_CR3","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1200\/JCO.2008.16.5704","volume":"26","author":"D Koeberle","year":"2008","unstructured":"Koeberle D, Saletti P, Borner M, et al: Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008, 26 (22): 3702-8. 10.1200\/JCO.2008.16.5704.","journal-title":"J Clin Oncol"},{"issue":"19","key":"3324_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011, 364 (19): 1817-25. 10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"15","key":"3324_CR5","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007, 25 (15): 1960-6. 10.1200\/JCO.2006.07.9525.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3324_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jpainsymman.2011.09.001","volume":"43","author":"D Romanus","year":"2012","unstructured":"Romanus D, Kindler HL, Archer L, et al: Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage. 2012, 43 (2): 205-17. 10.1016\/j.jpainsymman.2011.09.001.","journal-title":"J Pain Symptom Manage"},{"issue":"22","key":"3324_CR7","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1200\/JCO.2009.25.8285","volume":"28","author":"CM Moinpour","year":"2010","unstructured":"Moinpour CM, Vaught NL, Goldman B, et al: Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. J Clin Oncol. 2010, 28 (22): 3611-6. 10.1200\/JCO.2009.25.8285.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3324_CR8","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","volume":"28","author":"G Colucci","year":"2010","unstructured":"Colucci G, Labianca R, Di Costanzo F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010, 28 (10): 1645-51. 10.1200\/JCO.2009.25.4433.","journal-title":"J Clin Oncol"},{"issue":"33","key":"3324_CR9","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009, 27 (33): 5513-8. 10.1200\/JCO.2009.24.2446.","journal-title":"J Clin Oncol"},{"issue":"22","key":"3324_CR10","doi-asserted-by":"publisher","first-page":"3695\u2013701","DOI":"10.1200\/JCO.2007.15.6240","volume":"26","author":"J Bernhard","year":"2008","unstructured":"Bernhard J, Dietrich D, Scheithauer W, et al: Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44\/00-CECOG\/PAN.1.3.001. J Clin Oncol. 2008, 26 (22): 3695\u2013701-","journal-title":"J Clin Oncol"},{"issue":"14","key":"3324_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010, 362 (14): 1273-81. 10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"issue":"11","key":"3324_CR12","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","volume":"47","author":"U Pelzer","year":"2011","unstructured":"Pelzer U, Schwaner I, Stieler J, et al: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011, 47 (11): 1676-81. 10.1016\/j.ejca.2011.04.011.","journal-title":"Eur J Cancer"},{"issue":"4","key":"3324_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/COC.0b013e31818c08ff","volume":"32","author":"S Lee","year":"2009","unstructured":"Lee S, Oh SY, Kim BG, et al: Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol. 2009, 32 (4): 348-52. 10.1097\/COC.0b013e31818c08ff.","journal-title":"Am J Clin Oncol"},{"issue":"15","key":"3324_CR14","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/j.ejca.2010.07.023","volume":"46","author":"F Bonnetain","year":"2010","unstructured":"Bonnetain F, Dahan L, Maillard E, et al: Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer. 2010, 46 (15): 2753-62. 10.1016\/j.ejca.2010.07.023.","journal-title":"Eur J Cancer"},{"issue":"11","key":"3324_CR15","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1136\/gut.2010.216135","volume":"59","author":"L Dahan","year":"2010","unstructured":"Dahan L, Bonnetain F, Ychou M, et al: Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut. 2010, 59 (11): 1527-34. 10.1136\/gut.2010.216135.","journal-title":"Gut"},{"issue":"2","key":"3324_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00280-010-1329-6","volume":"67","author":"O Katopodis","year":"2011","unstructured":"Katopodis O, Polyzos A, Kentepozidis N, et al: Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol. 2011, 67 (2): 361-8. 10.1007\/s00280-010-1329-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"3324_CR17","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1002\/ijc.24270","volume":"124","author":"R Carter","year":"2009","unstructured":"Carter R, Stocken DD, Ghaneh P, et al: Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data. Int J Cancer. 2009, 124 (12): 2960-5. 10.1002\/ijc.24270.","journal-title":"Int J Cancer"},{"issue":"2","key":"3324_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jpainsymman.2008.02.007","volume":"37","author":"SG Eckhardt","year":"2009","unstructured":"Eckhardt SG, De Porre P, Smith D, et al: Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer. J Pain Symptom Manage. 2009, 37 (2): 135-43. 10.1016\/j.jpainsymman.2008.02.007.","journal-title":"J Pain Symptom Manage"},{"key":"3324_CR19","volume-title":"Computer-Based Health Evaluation System (CHES)","author":"ESD Inc., E.S.D","year":"2011","unstructured":"ESD Inc., E.S.D: Computer-Based Health Evaluation System (CHES). 2011, Innsbruck, Austria"},{"issue":"5","key":"3324_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993, 85 (5): 365-76. 10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"3324_CR21","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1634\/theoncologist.2009-0333","volume":"15","author":"A Zabernigg","year":"2010","unstructured":"Zabernigg A, Gamper EM, Giesinger JM, et al: Taste alterations in cancer patients receiving chemotherapy: a neglected side effect?. Oncologist. 2010, 15 (8): 913-20. 10.1634\/theoncologist.2009-0333.","journal-title":"Oncologist"},{"key":"3324_CR22","volume-title":"Acta Oncol","author":"EM Gamper","year":"2011","unstructured":"Gamper EM, Giesinger JM, Oberguggenberger A, et al: Taste alterations in breast and gynaecological cancer patients receiving chemotherapy: Prevalence, course of severity, and quality of life correlates. Acta Oncol. 2011"},{"issue":"1","key":"3324_CR23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998, 16 (1): 139-44.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3324_CR24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11605-007-0391-9","volume":"12","author":"S Crippa","year":"2008","unstructured":"Crippa S, Dominguez I, Rodriguez JR, et al: Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg. 2008, 12 (5): 783-93. 10.1007\/s11605-007-0391-9. discussion 793\u20134","journal-title":"J Gastrointest Surg"},{"issue":"10","key":"3324_CR25","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","volume":"101","author":"C Yoo","year":"2009","unstructured":"Yoo C, Hwang JY, Kim JE, et al: A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009, 101 (10): 1658-63. 10.1038\/sj.bjc.6605374.","journal-title":"Br J Cancer"},{"issue":"17","key":"3324_CR26","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1200\/JCO.2010.32.4459","volume":"29","author":"JS Temel","year":"2011","unstructured":"Temel JS, Greer JA, Admane S, et al: Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011, 29 (17): 2319-26. 10.1200\/JCO.2010.32.4459.","journal-title":"J Clin Oncol"},{"issue":"15","key":"3324_CR27","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1016\/j.ejca.2010.04.026","volume":"46","author":"MJ Aarts","year":"2010","unstructured":"Aarts MJ, Lemmens VE, Louwman MW, Kunst AE, Coebergh JW: Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome. Eur J Cancer. 2010, 46 (15): 2681-95. 10.1016\/j.ejca.2010.04.026.","journal-title":"Eur J Cancer"},{"issue":"9","key":"3324_CR28","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.ejca.2010.12.013","volume":"47","author":"N Cavalli-Bjorkman","year":"2011","unstructured":"Cavalli-Bjorkman N, Lambe M, Eaker S, Sandin F, Glimelius B: Differences according to educational level in the management and survival of colorectal cancer in Sweden. Eur J Cancer. 2011, 47 (9): 1398-406. 10.1016\/j.ejca.2010.12.013.","journal-title":"Eur J Cancer"},{"issue":"23","key":"3324_CR29","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1200\/JCO.2011.39.4411","volume":"30","author":"SK Lutgendorf","year":"2012","unstructured":"Lutgendorf SK, De Geest K, Bender D, et al: Social influences on clinical outcomes of patients with ovarian cancer. J Clin Oncol. 2012, 30 (23): 2885-90. 10.1200\/JCO.2011.39.4411.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3324_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/bjc.2012.186","volume":"107","author":"N Cavalli-Bj\u00f6rkman","year":"2012","unstructured":"Cavalli-Bj\u00f6rkman N, Qvortrup C, Sebjornsen S, et al: Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. Br J Cancer. 2012, 107 (1): 189-94. 10.1038\/bjc.2012.186.","journal-title":"Br J Cancer"},{"issue":"9","key":"3324_CR31","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/pon.1308","volume":"17","author":"AM May","year":"2008","unstructured":"May AM, Duivenvoorden HJ, Korstjens I, et al: The effect of group cohesion on rehabilitation outcome in cancer survivors. Psychooncology. 2008, 17 (9): 917-25. 10.1002\/pon.1308.","journal-title":"Psychooncology"},{"issue":"5","key":"3324_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/pon.1924","volume":"21","author":"N Rottmann","year":"2012","unstructured":"Rottmann N, Dalton SO, Bidstrup PE, et al: No improvement in distress and quality of life following psychosocial cancer rehabilitation. A randomised trial. Psychooncology. 2012, 21 (5): 505-14.","journal-title":"A randomised trial. Psychooncology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-390.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-390\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-390","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T23:47:47Z","timestamp":1498002467000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3324"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-390","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,6]]},"article-number":"390"}}